Finally, database screening showed that augmented ALS2 expression correlates with poor patient survival in a subgroup of cancers, including adrenocortical carcinoma, papillary renal cell carcinoma and lung squamous cell carcinoma, although contrasting results were found in others, such as leukemia and CCRCC (Supplementary Fig. 4). The gene discussed is ALS2; the disease is cancer.